Riskpilot← Back to searchSign inGet full accessDexact Medical AB
ABBankruptOrg 5569219875Activities of advertising agencies · NACE 7311Est. 20130 employees
Revenue 2020
SEK 48K
+12% vs 2019
EBITDA margin
-22.9%
+86% vs 2019
Equity ratio
15.0%
Financial strength
Net profit 2020
SEK -20K
+78% vs 2019
| Revenue | SEK 48K | +12% |
| EBITDA | SEK -11K | +86% |
| Net profit | SEK -20K | +78% |
| Total assets | SEK 639K | -2% |
| Equity | SEK 96K | +150% |
| Employees | 0 | — |
Legal name
Dexact Medical AB
Org number
5569219875
Legal form
Aktiebolag
NACE code
7311 · Activities of advertising agencies
Founded
8 februari 2013
Share capital
SEK 90 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2020-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöternaStyrelsen ska bestå av 3 styrelseledamöter och 0 styrelsesuppleanter.
Company purpose
Föremålet för bolagets verksamhet är att bedriva marknads- etableringar och försäljning av produkter inom medicin och hälsovård samt därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 43 | 48 |
| Staff expenses | — | — | — | — | — |
| EBITDA | — | — | −173 | −78 | −11 |
| Depreciation & amort. | −0 | −0 | −15 | −23 | −9 |
| EBIT | 0 | 0 | −188 | −101 | −20 |
| Net financials | — | — | — | −2 | — |
| Profit before tax | 0 | 0 | −188 | −92 | −20 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | 0 | 0 | −188 | −92 | −20 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|
| Total assets | 87 | 886 | 747 | 655 | 639 |
| Equity | 87 | 87 | −101 | −193 | 96 |
| Long-term debt | 0 | 100 | 0 | 0 | 0 |
| Short-term debt | 0 | 699 | 849 | 849 | 543 |
| Total debt | — | 799 | 849 | 849 | 543 |
EBITDA margin
-22.9%
This company
15.8%
Market median
-245% vs market
20162020
Equity ratio
15.0%
This company
38.2%
Market median
-61% vs market
20162020
Return on equity
-20.8%
This company
18.4%
Market median
-213% vs market
20162020
Net profit margin
-41.7%
This company
8.1%
Market median
-615% vs market
20162020
Asset turnover
0.08×
This company
1.12×
Market median
-93% vs market
20162020
Debt / equity
5.66×
This company
0.62×
Market median
-813% vs market
20162020
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
DK Audit | Audit | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2022 | |
| Board of Directors | 2022 | |
| Former (2) | ||
| Chairman | 2020 – 2022 | |
| Board of Directors | 2020 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
PEAS Institut AB
Dexact Medical AB Board members of Dexact Medical AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Daniel Kenneth Önell | Audit | 0 companies |
| Fariba Nayeri | Chairman | 0 companies |
| Tayeb Nayeri | Chairman | 0 companies |
| Andreas Erik Lindgren | Board of Directors | 0 companies |
| Per Olof Knut Stålhandske | Board of Directors | 0 companies |